Ogivri will be launched at a competitive discount for customers to help ensure increased access to treatment for thousands of HER2-positive breast and gastric cancer patients, said Biocon

Reliance Industries stock will remain in focus as RIL is seen as a major beneficiary after Jio announced tariff hike on Sunday.

A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?

Biocon reports robust growth across all business segments: Biologics, small molecules, branded formulations and research services

Ogivri is the biosimilar version of Swiss drug maker Roches Herceptin, a breast cancer and gastric cancer drug with sales of $6.9 billion a year worldwide

Ogivri (Trastuzumab), jointly developed by Biocon and Mylan, is the biosimilar version of Swiss drug maker Roche's Herceptin.

After a long search, Infosys named Salil S Parekh as its new CEO and Managing Director.

Ogivri is the first United States Food and Drug Administration (USFDA) approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the US, the two companies said in a joint statement.

Tech-savvy health care is making a difference to both the well-off and those with limited resources and access.

Indian drug makers are slugging it out with Big Pharma over launch of biosimilars. Will they be able to hold their fort in this emerging space?

The US is mounting pressure on India to agree to its terms in pharma IP protection. How long can India resist?

In the seven years since, Mylan Inc has invested around $3 billion on acquisitions in India. It now regards India not just as a global sourcing hub, but also as a market.

Roche has sought an injunction against two pharma companies - the Bangalore based Biocon and US-based Mylan. The two companies have launched a co-developed biosimilar of the drug Herceptin, which treats certain types of breast cancers. Formerly, Roche held the patent for Herceptin, but unexpectedly gave it up last year.